HLB Therapeutics Co Ltd banner
H

HLB Therapeutics Co Ltd
KOSDAQ:115450

Watchlist Manager
HLB Therapeutics Co Ltd
KOSDAQ:115450
Watchlist
Price: 2 970 KRW -1.82% Market Closed
Market Cap: ₩250.6B

Wall Street
Price Targets

Price Targets Summary
HLB Therapeutics Co Ltd

There are no price targets for HLB Therapeutics Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
HLB Therapeutics Co Ltd Competitors:
Price Targets
RCKT
Rocket Pharmaceuticals Inc
66% Upside
ACIU
AC Immune SA
204% Upside
CSGP
CoStar Group Inc
80% Upside
LASR
nLIGHT Inc
-18% Downside
OFIX
Orthofix Medical Inc
57% Upside

Revenue
Forecast

10% / Year
Past Growth
-2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
10% / Year
Past Growth
-2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 13 years the compound annual growth rate for HLB Therapeutics Co Ltd's revenue is 10%. The projected CAGR for the next 6 years is -2%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HLB Therapeutics Co Ltd's stock price target?
Not Available

HLB Therapeutics Co Ltd doesn't have any price targets made by Wall Street professionals.

What is HLB Therapeutics Co Ltd's Revenue forecast?
Projected CAGR
-2%

For the last 13 years the compound annual growth rate for HLB Therapeutics Co Ltd's revenue is 10%. The projected CAGR for the next 6 years is -2%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett